scan after 8 weeks of erlotinib showed continued significant decrease in the right upper lobe mass and mediastinal lymphadenopathy. Table 1 Tissue Biopsy Characteristics In April 2010, the patient underwent right pneumonectomy with lymph
Search Results
EGFR-Mutated Lung Cancer With T790M-Acquired Resistance in the Brain and Histologic Transformation in the Lung
Kevin S. Scher, Juan-Sebastian Saldivar, Michael Fishbein, Alberto Marchevsky, and Karen L. Reckamp
Participation of Patients With Limited English Proficiency in Gynecologic Oncology Clinical Trials
Soledad Jorge, Shatreen Masshoor, Heidi J. Gray, Elizabeth M. Swisher, and Kemi M. Doll
ethnicity patients represented 45.7% of the LEP group. Table 1. Baseline Patient Characteristics In total, 7.1.% of patients were enrolled in a clinical trial. Research participation was significantly lower among patients with LEP (2.2%) compared
Impact of Anti-HER2 Therapy Alone and With Weekly Paclitaxel on the Ovarian Reserve of Young Women With HER2-Positive Breast Cancer
Matteo Lambertini, Marcello Ceppi, Richard A. Anderson, David A. Cameron, Marco Bruzzone, Maria Alice Franzoi, Claudia Massarotti, Sarra El-Abed, Yingbo Wang, Christophe Lecocq, Paolo Nuciforo, Rebecca Rolyance, Lajos Pusztai, Joohyuk Sohn, Maria Maddalena Latocca, Luca Arecco, Barbara Pistilli, Kathryn J. Ruddy, Alberto Ballestrero, Lucia Del Mastro, Fedro A. Peccatori, Ann H. Partridge, Cristina Saura, Michael Untch, Martine Piccart, Serena Di Cosimo, Evandro de Azambuja, and Isabelle Demeestere
Tumor Characteristics AMH values differed significantly at the 3 time points ( P <.001; Figure 2A ). At screening/baseline, median AMH levels were 1.29 ng/mL (IQR, 0.56–2.62 ng/mL). After 2 weeks of anti-HER2 treatment alone, a small reduction in
Role of Immunotherapy for Renal Cell Cancer in 2011
Saby George, Roberto Pili, Michael A. Carducci, and Jenny J. Kim
in search of biomarker of response to IL-2 that can be validated in subsequent studies. Table 1 Response by Baseline Characteristics The therapeutic armamentarium for metastatic RCC considerably expanded in the past several years with
Benefit of Postoperative Radiotherapy for Patients With Nonmetastatic Adrenocortical Carcinoma: A Population-Based Analysis
Kan Wu, Xu Liu, Zhihong Liu, Yiping Lu, Xianding Wang, and Xiang Li
nonmetastatic ACC using a large population-based database. In addition, we sought to identify a subset of patients with ACC who may be more likely to benefit from adjuvant radiation based on their tumor characteristics. Patients and Methods Study
CLO20-067: Clinical Characteristics, Management and Outcome of Incidental Pulmonary Embolism in Cancer Patients: A Case-Control Study
Sai-Ching Yeung, Aiham Qdaisat, Mona Kamal, Aisha Al-Breiki, Biman Goswami, Carol C. Wu, Shouhao Zhou, Terry Rice, and Kumar Alagapan
Incidental pulmonary embolisms (IPE) are commonly discovered in cancer patients during their cancer staging and surveillance imaging studies. Examining the clinical characteristics and outcomes of these incidents in cancer patients may guide the
Systemic Treatment Strategies and Outcomes of Patients With Synchronous Peritoneal Metastases of Gastric Origin: A Nationwide Population-Based Study
Niels A.D. Guchelaar, Bo J. Noordman, Marion W. Welten, Myron T. van Santen, Micha J. de Neijs, Stijn L.W. Koolen, Rob H.A. Verhoeven, Esther Oomen-de Hoop, Pieter C. van der Sluis, Sjoerd M. Lagarde, Hanneke W.M. van Laarhoven, Ignace H.J.T. de Hingh, Geert-Jan Creemers, Bianca Mostert, Bas P.L. Wijnhoven, and Ron H.J. Mathijssen
that includes all patients with newly diagnosed cancer via a direct linkage to the national pathologic archive and the Dutch Hospital Data. Trained registrars of the NCR collect patient, tumor, and treatment characteristics from the hospital’s medical
CLO22-090: Patient Characteristics, Treatment Patterns, and Clinical Outcomes of Patients With Advanced HER2-Low Breast Cancer
Alexandre Hikiji Watanabe, Connor Willis, Melissa Pavilack-Kirker, Clara Lam, Leah Park, Sandhya Mehta, Jackie Kwong, Anindit Chhibber, Hillevi Bauer, Sabrina Ilham, Diana Brixner, and David Stenehjem
240 (46.0%) were HER2-low, 142 (27.2%) HER2+, 46 (8.8%) HER2 IHC 0, and 94 (18.0%) had unknown/incomplete HER2 results. Among the HER2-low patients, 198 (82.5%) were HR+, 40 (16.7%) were HR-, and 2 (0.8%) were unknown. The tumor characteristics and
Effect of Patient Navigation on Completion of Lung Cancer Screening in Vulnerable Populations
Sheena Bhalla, Vijaya Natchimuthu, Jessica L. Lee, Urooj Wahid, Hong Zhu, Noel O. Santini, Travis Browning, Heidi A. Hamann, David H. Johnson, Hsienchang Chiu, Simon J. Craddock Lee, and David E. Gerber
. Demographic characteristics were collected from the EHR and/or patient report at baseline. Comorbidities were categorized using the Charlson comorbidity index. 23 Performance of LDCT, Lung-RADS results, and other steps in the LCS process were captured through
Serial Assessment of Urinary Incontinence in Breast Cancer Survivors Undergoing (Neo)Adjuvant Therapy
Christopher P. Chung, Carolyn Behrendt, Louise Wong, Sarah Flores, and Joanne E. Mortimer
classified according to the IIQ-7 score as major (33–99), moderate (5–29), or no impact (0). Statistical Analyses For this exploratory study, statistical significance ( P <.05) was unadjusted for multiple hypothesis testing. Demographic characteristics (age
